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Abstract 
Supplement manufacturers are widely unregulated and are only held accountable for 
products if their supplement is shown to cause harm. To take advantage, some 
manufacturers use false or sensationalized claims that have little or no scientific backing. 
Due to the lack of testing for many supplements, this study will seek to determine 
multiple effects of the weight loss supplement, Shred Matrix. 
PURPOSE: The purpose of this study was to 1) examine the acute effects of the weight 
loss aid, Shred Matrix, on hemodynamic responses, substrate utilization, endurance, 
arterial compliance, and body water distribution; 2) To investigate the differences 
between athletes and non-athletes on the previously stated measures. 
METHODS: 31 subjects underwent a randomized, double-blind, crossover design study 
and were given a placebo or Shred Matrix on two separate days. Baseline measures of all 
variables were assessed prior to exercise. During exercise, each subject ran on a treadmill 
at 80% VO2 Max until volitional fatigue. While running, HR, VO2, and respiratory 
exchange ratio were continuously monitored. Immediately post-exercise, arterial 
elasticity was measured at 0, 10, 20, and 40 minutes. Body fluid analyses were performed 
at 5 and 30 minutes post-exercise. PWV was measured at 5, 15, 25, and 35 minutes post-
exercise.  
RESULTS: Significant condition differences existed for ECF in non-athlete males 
(p=.023). Carotid to radial PWV was significant (p=.01). There was a significant 
condition*time interaction with Shred Matrix having a higher PWV for the carotid to 
femoral segment (p=.003) and the femoral to distal segment (p=.018). LAE was 
significantly lower for Shred Matrix (p=.003). SBP was conditionally higher (p=.001), as 
was DBP (p=.003), MAP (p=.001), and PP (p=.035). There were significant 
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condition*time interactions for PR (p=.001) and SV (p=.016). VR was conditionally 
significant (p=.05). RER while running was significantly higher (p=.034) with Shred 
Matrix. Only female non-athletes ran longer on Shred Matrix (p=.033). 
CONCLUSION: Shred Matrix caused multiple negative effects in hemodynamics and 
arterial compliance. Consumers should educate themselves before purchasing 
supplements and visit with a physician to determine any preexisting conditions that might 
be cause for concern. 
KEYWORDS: Shred Matrix, supplement, weight- loss 
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CHAPTER I 
INTRODUCTION 
 
 By law, dietary supplement manufacturers are not required to receive Food and 
Drug Administration (FDA) approval before producing or selling a dietary product. This 
means that manufacturers are able to introduce substances into their products without 
labeling or including dosage sizes. Companies are also able to invent false or 
sensationalized claims as long as their disclaimer reads, “these statements have not been 
evaluated by the FDA.” Their only obligation is to register the product and report 
instances of adverse effects. The policy is reactionary; action against a harmful 
supplement is not taken unless catastrophic events happen to draw attention to a harmful 
product or ingredient (FDA, 2015). 
 A well-known incident of an ingredient in supplements being harmful is 
ephedrine in the early 2000s. A report published by the FDA in 2003 performed a meta-
analysis over ephedrine and ephedrine-containing products. Their results found a modest 
increase in fat loss, but a two to three fold increase for the risk of nausea, vomiting, 
psychiatric symptoms, autonomic hyperactivity, and palpitations. There were also reports 
of a total of five deaths from the ingredient (Shekelle, Morton, Maglione, et al. 2003). 
Consequently, the FDA banned ephedrine four months later. 
 With over 1500 establishments that manufacture dietary supplements (Karns, 
2000) there is a need for products and ingredients to be tested to substantiate claims of 
efficacy. Companies that possess research backing their products will have more 
credibility for consumers. They will also provide evidence for new findings that may 
allow ingredients to treat diseases where medication is ineffective or unwanted. 
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Study Purpose 
 The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke 
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse 
wave velocity, and body water distribution; 2) To investigate the differences between 
athletes and non-athletes on the previously stated measures. 
Research Questions 
1. Was there a significant increase in fat metabolism when the weight loss aid, 
Shred Matrix, if consumed prior to exercise? 
2. What were the changes in exercise HR, exercise diastolic and systolic BP? 
3. Was there a significant effect on stroke volume? 
4. Was there a significant effect on ejection time? 
5. Was there an increase in exercise endurance? 
6. Was there a change in arterial compliance? 
7. Was there a significant effect on pulse wave velocity? 
8. Was there a change in intracellular and/or extracellular body water? 
Hypotheses 
1. There was a greater amount of fat metabolism with Shred matrix during 
exercise. 
2. Shred Matrix resulted in lower increases in HR, diastolic and systolic blood 
pressures at different time points compared to placebo. 
3. There was a significant increase in stroke volume. 
4. There was an increase in cardiac ejection time. 
5. Shred Matrix resulted in increased time to exhaustion. 
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6. There was an increase in large and small arterial elasticity. 
7. There was a decrease in pulse wave velocity. 
8. There was an increase in extracellular water. 
 
Significance of the Study 
 The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines 
dietary supplements as “products that, among other things, are intended for ingestion to 
supplement the diet, labeled as dietary supplements, and not represented as conventional 
foods or as a sole items of a meal or diet” (Dietary Supplement Health and Education Act 
of 1994). Under the DSHEA, supplements are generally considered as being safe and the 
Food and Drug Administration (FDA) has no authority to regulate the market unless a 
product has been shown to be dangerous to the public. Supplement manufacturers are not 
required to provide evidence for claims so long as there is no claim that a product can 
“treat, prevent, or cure” a disease (GAO-10-662T). With such a large amount of freedom 
given to manufacturers, there is a need for more research into supplementation to provide 
accountability for businesses creating these supplements and to educate consumers on the 
effectiveness of their purchases. 
 Shred Matrix claims to be a weight loss supplement and mood enhancer designed 
specifically for athletes. There are several active ingredients contained within the 
supplement that have been previously studied and shown to support those claims. It is 
important that this study observe the effects of Shred Matrix on heart rate, blood pressure, 
substrate utilization, endurance, arterial compliance, stroke volume, ejection time, and 
body water distribution to determine if their claims are substantiated and to add to the 
body of knowledge concerning the ingredients listed. 
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Delimitations 
1. Since arterial elasticity is affected by age, only males and females between the 
ages of 18-40 were allowed to participate in the study. 
2. Individuals suffering from diseases that prevent subjection to maximal testing 
were excluded. These included hypertension, metabolic, and cardiovascular 
diseases. 
3. Individuals suffering from disabilities that prevented maximal testing were 
excluded. These included joint injuries or chronic pain. 
4. Individuals who were currently or took ergogenic aids other than caffeine within 
the previously 30 days before testing were excluded. 
5. Subjects were required to be adequately hydrated before testing. 
Limitations 
1. The study might not be representative of the population due to all participants 
being volunteers and not being randomly sampled. 
2. Health history and medical information were gathered through self-report.  
3. Participants were asked to refrain from ingesting caffeine, alcohol, or engaging in 
intense exercise for at least 24 hours before testing, but diet and activity were not 
monitored. 
Assumptions 
1. Subjects performed each maximal test and volitional fatigue test to the best of 
their ability. 
2. Subjects arrived fasted and adequately rested on testing days. 
3. Accurate health history and medical information were provided. 
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4. The equipment used was reliable and provided accurate information for each 
testing session. 
Operational Definitions 
Athlete: Having a VO2MAX (ml/kg/min) deemed “excellent” according to age for females 
and males as determined by either the greatest measure gathered by metabolic cart or 
time to exhaustion during the Bruce Protocol (Nunes, 2005). 
Non-athlete: Having a VO2MAX (ml/kg/min) deemed less than “excellent” according to 
age for females and males as determined by either the greatest measure gathered by 
metabolic cart or time to exhaustion during the Bruce Protocol (Nunes, 2005). 
Hydration: Hydration status was deemed adequate when urine specific gravity measured 
1.010 and lower as determined by a clinical urine refractometer (Case et al., 2000). 
PAR-Q: PAR-Q (Physical activity readiness questionnaire) is a screening tool that is 
designed to determine whether a subject may perform the exercise in a safe and risk free 
manner. 
Ergogenic Aid: are any external influences that can be determined to enhance 
performance in high- intensity exercises. 
 
  
CHAPTER II 
REVIEW OF THE LITERATURE 
 
 The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (heart rate, blood pressure, stroke volume, 
ejection time) substrate utilization, endurance, arterial compliance, pulse wave velocity 
and body water distribution; 2) To investigate the differences between athletes and non-
athletes on the previously stated measures. 
 Unlike weight loss supplements tailored to be taken by a sedentary and obese 
population, Shred Matrix claims to be “a weight loss system designed for athletes.” 
According to the manufacturers this is achieved through an eight stage approach 
consisting of: Stages 1 and 2 increase energy and ramp up metabolism. Stages 3 and 4 
crush hunger. Stage 5 balances mood and enhances well-being. Stage 6 maintains sharp 
mental focus without jitters. Stage 7 eliminates excess water. Stage 8 contains a 
trademarked Sugar Stop TM and enzyme aid matrix. 
Ingredients Affecting Body Fluid 
 Weight loss is also obtained from this supplement through loss of water. There are 
two ingredients that are listed in Shred Matrix that have been associated with water loss, 
uva ursi leaf and dandelion root. The American Medical Association classifies both 
dandelion root and uva ursi leaf as diuretics to increase body fluid loss (Miller, 1998).  
Uva Ursi Leaf 
 Uva ursi is most commonly used as a natural remedy to treat urinary tract 
infections. However on review cited a study done in animals where uva ursi acted as a 
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diuretic without impacting potassium or sodium levels (Head, 2008). No human studies 
for uva ursi’s effects on body fluid were discovered while reviewing literature. 
Dandelion Root 
 A study was designed by Clare et al. (2009) to determine the diuretic effects of 
dandelion root on 28 females aged 18-65. The trials took place over a 4 day period where 
subjects monitored their fluid intake and urine excretion with or without the supplement. 
The results showed a significant increase in urination following dosages of dandelion root 
with a decrease near baseline levels the day following supplementation. The authors 
revealed that the test was not blinded, there were a small number of subjects, fluid input 
was self-monitored, there was no correction for water from food, and limited baseline 
values for urine output. Despite the limitations, the authors felt the results warranted 
further investigation into the natural diuretic, dandelion root (Clare, Conroy, & Spelman, 
2009). 
Ingredients Affecting Hemodynamics 
 Shred Matrix contains ingredients that both positively and negatively affect 
hemodynamics. This may lead to either higher central pressures, lower, or they may be 
cancelled out and remain unchanged.  
Garlic 
 Garlic has been shown to lower blood pressure in hypertensive subjects. Seventy-
nine subjects took part in a 12-week double-blind, randomized, placebo-controlled 
parallel trial. Subjects were split between four groups, 3 varying garlic groups and one 
placebo group. The results of the study showed that garlic supplementation was superior 
to placebo in lowering systolic blood pressure in subjects with hypertension in the higher 
dosage groups (Ried, Frank, & Stocks, 2013). 
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 In trained cyclists, there was no significant difference found in blood pressure 
under hypoxic conditions. Nine healthy subjects underwent 7 days of garlic 
supplementation, a 7 day washout period, and then another 7 day supplementation period 
with maximal testing pre and after each supplementation period. All exercise testing was 
done on cycle ergometers. Treatments were applied in a randomized, single-blind, 
crossover fashion.  The results of the study concluded that under hypoxic conditions in 
trained cyclists, there was no significant decrease in SBP or DBP (Morris, Beloni, & 
Wheeler, 2013). 
Caffeine 
 Caffeine is one of the primary ingredients listed in Shred Matrix. In 2004, the 
World Anti-Doping Agency removed caffeine from its list of banned substances, and 
more than 60 peer-reviewed articles have been published on caffeine and its role in sport 
performance enhancement (Desbrow & Leveritt, 2007). Caffeine has been shown to 
increase systolic and diastolic blood pressure through increases in peripheral vascular 
resistance at rest. One study performed on young, healthy, normotensive men volunteered 
to take part in a double-blind cross-over study. Subjects came in on two different days 
separated by at least 48 hours. They were randomly assigned either 3.3 mg/kg caffeine or 
a placebo and rested for 40 minutes. Afterwards, subjects performed multiple 3 minute 
cycling stages of increasing intensity. After one hour of rest, subjects performed maximal 
cycling testing. Results showed increases in systolic and diastolic blood pressure and also 
increases in peripheral vascular resistance. The authors speculate that caffeine inhibited 
the adenosine receptor responsible for vasodilation. The resultant vasoconstriction caused 
increases in central pressure (Sung, Lovallo, Pincomb, & Wilson, 1990). 
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 Another study observed the hemodynamic responses to caffeine at rest. Fifteen 
males, aged 20-35 years were blinded and received either caffeinated or a placebo 
beverage. Every ten minutes measures were taken, up to 40 minutes post ingestion, while 
subjects remained in a semi-recumbent position. Results showed significant increases in 
systolic and diastolic pressure and increased systemic vascular resistance (Pincomb et al., 
1985). 
Ingredients Affecting Arterial Elasticity 
Turmeric 
Turmeric is derived from the plant Curcuma longa and has many potential health 
benefits, including potential increases in arterial elasticity. One of the few studies 
observing turmeric’s effects on arterial elasticity measured differences between 51 
postmenopausal women separated into four groups. The four groups consisted of two 
exercise groups, one of which also received turmeric, and two non-exercise groups, one 
of which received turmeric. The four groups ingested 150mg of turmeric or a placebo 
each day for 8 weeks and the exercise groups were given an aerobic workout plan. The 
results of the experiment showed positive increases in carotid arterial elasticity for all 
groups except the non-exercise placebo group. Turmeric only supplementation showed 
positive effects similar to the exercise only group, and combined exercise and turmeric 
demonstrated the greatest increases in carotid arterial compliance (Akazawa et al., 2013). 
Caffeine 
 Caffeine’s effects on hemodynamic may also relate to changes in arterial 
elasticity. Seven healthy subjects ingested either 250mg of caffeine through coffee or 
drank decaffeinated coffee on two different days divided by at least one week. After 
ingestion, subjects were observed for 90 minutes in the supine position with carotid to 
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femoral pulse wave velocity measurements taken every 30 minutes. Results showed acute 
increases in vascular stiffness, even after adjustment for blood pressures (Mahmud & 
Feely, 2001). 
Ingredients Affecting Endurance 
 There is a relationship between endurance activities and fat oxidation. The ability 
to perform for longer periods of time at a given intensity means that more fat is being 
burned to meet energy demands. As a weight loss supplement, Shred Matrix contains 
ingredients that have been shown to increase endurance, and thus burn more fat and 
lower body mass. The ability to utilize more fat comes in part from a sparing of glucose. 
A negative fat balance can also be had by maintaining steady insulin levels after ingestion 
of carbohydrates to avoid storing glucose in adipose tissue. Utilizing both approaches 
from the ingredients in the product allow fat to be utilized more as an energy source and 
have less fat stored. 
Caffeine 
 Caffeine has previously been shown to improve performance by promoting 
plasma free fatty acid (FFA) mobilization and sparing muscle glycogen (Spriet et al., 
1992), however later studies credit better performance to increases in central nervous 
system (CNS) stimulation and muscle recruitment (Cox et al., 2002) 
 Aside from reported physiological effects of caffeine, there may be a 
psychological component to increasing endurance performance (Marcora, Staiano, & 
Manning, 2009).  Adenosine, a neurotransmitter, is responsible for inhibiting excitatory 
neurotransmitters leading to reduced arousal, increased sleep, and feelings of fatigue. 
During the day or throughout exercise, adenosine levels progressively increase until 
fatigue or exhaustion sets in. Researchers speculate that adenosine may be partially 
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responsible for fatigue in endurance exercise (Davis et al., 2003). Caffeine directly 
inhibits adenosine receptors and may explain in part why ingestion of caffeine leads to 
increases in exercise duration (Cox et al., 2002). Research on rats has already shown that 
low doses of caffeine inhibit adenosine and was responsible for longer exercise durations 
until exhaustion (Davis et al., 2003). 
Eleutherococcus senticosus 
 Eleutherococcus senticosus (ES) is a shrub native to forests in Russia, China, 
Japan, and Korea. The active ingredients in ES are known as eleutherosides. The plants 
and its derivatives are normally safe, but diarrhea and insomnia have been reported as 
possible side effects(Kuo, 2010). 
 Nice recreationally trained college males were given either 800mg/d of ES or a 
placebo during an 8 week randomized, double-blind, placebo-controlled with a crossover 
design study to determine its effects on endurance capacity, cardiovascular functions, and 
metabolism. Pre and post-test values were measured on a bicycle ergometer at 75% VO2 
peak. The results of the study showed a 12% increase in VO2 peak, endurance time 
increased 23%, and max HR increased 4%. The authors attributed the positive endurance 
results to a shift of burning more fatty acids as a fuel instead of glucose (Kuo, 2010). 
Biotin and Chromium 
 The essential trace mineral, chromium, was identified over 40 years ago as being 
a part of lipid and carbohydrate metabolism. Since then, there have been multiple studies, 
both animal and human, that demonstrate the efficacy of chromium supplementation for 
type 2 diabetes (Albarracin, Fuqua, Evans, & Goldfine, 2008). Biotin is part of the B 
vitamin group, specifically B7. It is water soluble and plays a role in carbohydrate and 
lipid metabolism. Biotin affects metabolism by stimulating genes that affect glycaemic 
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control in the pancreas and liver. It also suppresses phosphoenolpyruvate carboxykinase, 
which is one of the enzymes involved in gluconeogenesis. This suppression will inhibit 
new glucose molecule formation, thus maintaining lower blood glucose levels 
(Albarracin et al., 2008). 
 Four hundred and forty-seven subjects with type 2 diabetes and HbA1c ≥7 were 
divided into and experiment or control group for 90 days. HbA1c refers to the amount of 
hemoglobin that is combined with blood glucose to become glycated. Each group 
received either biotin with chromium picolinate or a placebo. The results of the study 
showed a significant improvement in fasting blood glucose levels and HbA1c, especially 
when HbA1c levels pretest were ≥10 (Albarracin et al., 2008). 
 Biotin has been studied extensively in diabetic animals. “In genetically diabetic 
KK mice and in Otsuka Long Evans Tokushima Fatty (OLETF) rats, biotin treatment 
lowered postprandial glucose concentration and improved tolerance to glucose.” This 
means that biotin supplementation may lower glucose absorption, thus lowering insulin 
response and preventing excess carbohydrate from being stored as fat (Fernandez-Mejia, 
2005). 
Capsaicin 
 Capsaicin is the component generally found in cayenne pepper and is responsible 
for its hot and spicy flavor. Its use has been studied with results indicating that both 
energy expenditure and fat oxidation increased (Ahuja, Robertson, Geraghty, & Ball, 
2006). Other studies suggest that capsaicin may be used to lower blood glucose by 
increasing insulin levels in healthy human subjects (Dömötör, Szolcsányi, & Mózsik, 
2006). At this time there were no studies found investigating the effects of capsaicin on 
diabetic humans. 
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 Eight male mice, aged one week, were fed a high fat diet for a total of 20 weeks. 
They were divided at week 10 into an experiment and control group. The experimental 
group was administered capsaicin with their high fat diet while the control continued to 
receive only the high fat diet. The group receiving capsaicin had significantly lower 
levels of insulin and glucose 60 minutes after ingesting glucose. The results showed that 
capsaicin protected against glucose intolerance in obese mice (Kang et al., 2010).  
 Twelve healthy volunteers participated in a crossover study designed to test the 
effects of capsaicin on blood glucose levels. Baseline levels of insulin and fasted blood 
glucose were taken. Subjects were then administered 75g of glucose followed by 5g of 
either capsaicin or a placebo. With capsaicin ingestion, lower blood glucose levels were 
observed at 30 and 45 minutes post ingestion. Insulin levels were higher than the placebo 
group during the time period. Afterwards, insulin levels dropped back to basal levels for 
the experimental group while insulin levels continuously decreased below basal levels in 
the control (Weerapan Khovidhunkit, 2009). 
 Dömötör et al. studied fourteen healthy human subjects. Each subject was self-
controlled and was administered 75mg of glucose orally either with or without capsaicin. 
Blood glucose, insulin, and glucagon levels were measured every 15 minutes for 4 hours. 
The study found that capsaicin was responsible for an initial increase in insulin levels 
which demonstrated an increase in absorption. Glucagon levels also increased 
independently from insulin. The authors speculated that capsaicin was responsible for 
stimulating afferent nerves responsible for glucagon synthesis (Dömötör et al., 2006). 
Gymnema Sylvestre 
 Gymnema sylvestre is a plant that acts to improve blood glucose levels in two 
ways. First, it acts to stimulate insulin secretion (Al-Romaiyan et al., 2010). Second, it 
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suppresses glucose absorption in the small intestine. This will cause a slower rise in 
blood glucose and can become easier to control (Kurian, Manjusha, Nair, Varghese, & 
Padikkala, 2014). 
Banaba Extract 
 Banaba is touted as being an insulin mimetic, meaning it acts in the way that 
insulin does to decrease blood glucose. It has primarily been used in folk medicine in 
Southeast Asia to treat diabetes. According to some studies, it may also be beneficial in 
controlling hyperlipidemia and act as an anti-inflammatory (Miura, Takagi, & Ishida, 
2012). 
 Subjects with mild diabetes were recruited to perform a randomized, double-blind 
study for 6 months to determine the effectiveness of Banaba extract and other 
components on blood glucose. The results showed no significant difference in blood 
glucose homeostasis. However, the researchers did find that there was a decrease in 
biomarkers that signal inflammation. The author speculated there may not have been a 
significant difference in blood glucose levels due to the multiple herbs in their cocktail 
interfering with each other (Kim et al., 2012). 
 Six-week-old mice were fed a high fat diet for 9 weeks, with the experimental 
mice receiving corosolic acid, derived from Banaba leaves, and the control receiving only 
the high fat diet. Mice receiving the corosolic acid had 10% less body weight than the 
control. Plasma glucose was 23% lower for the experimental group, and insulin was also 
lower by 41%. This suggested that the corosolic acid mice had higher insulin sensitivity. 
The lower weight was explained through activation of the peroxisome proliferator-
activated receptor (PPAR), which is responsible for gene expression that affects lipid 
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metabolism. PPAR activation from corosolic acid would lead to higher level of fat 
oxidation (Yamada et al., 2008). 
 Twelve subject, 7 males and 5 females, were recruited to test the efficacy of 
Banaba extract on blood glucose. Fasting blood glucose was measured, followed by a 
540kcal meal consisting of 100% starch. Plasma glucose levels were then measured at 30, 
60, and 120 minutes after ingestion. For the next two weeks, Banaba extract was 
administered orally every morning. No changes in plasma glucose were reported, 
however there was an improvement in BMI (Tsuchibe, Kataumi, Mori, & Mori, 2006). 
Turmeric 
 Along with increasing arterial elasticity mentioned earlier, turmeric has also been 
found to possess antioxidant and antimutagenic capabilities, while also inhibiting 
glucosidase enzymes (Gupta et al., 2013). Alpha and beta glucosidase are responsible for 
breaking down compound carbohydrates into simpler sugars that will lead to high blood 
glucose levels. Inhibiting these enzymes will cause blood glucose to rise at a slower rate 
and be easier to manage (Lekshmi, Arimboor, Indulekha, & Nirmala Menon, 2012). 
 Type 2 diabetic subjects participated in a randomized, double-blind, and placebo 
controlled study to determine the efficacy of turmeric on proteinuria, serum transforming 
growth factor, tumor necrosis factor, and urinary levels of interleukin-8. The primary 
results of the study are beyond the scope of this review, but the researchers also observed 
fasted plasma glucose and 2 hours postprandial blood glucose. They found no significant 
difference for either category (Khajehdehi et al., 2011). 
 Genetically diabetic mice were divided into 3 groups of 5 mice each by body 
weight and blood glucose. The control was fed the basal diet only, while the two 
experimental groups were fed turmeric either .2 or 1g/100g of the diet. After 4 weeks 
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blood samples were obtained. The control group saw a significant rise in blood glucose 
after 4 weeks of feeding while both experimental groups stayed the same. This led the 
authors to speculate that turmeric supplementation may lead to preventing type 2 diabetes 
(Kuroda et al., 2005). 
 Fourteen healthy subjects in a crossover trial ingested 75g of glucose together 
with either 6g of Curcumin longa or a placebo. Blood samples were taken using finger 
prick to measure glucose and insulin levels at 15, 30, 45, 60, 90, and 120 minutes. The 
results of the study concluded that there was no significant difference in plasma glucose 
from an acute dose of Curcumin longa. However, the study show significance in insulin 
levels after 30 minutes postprandial up to 1 hour. The author speculated that Curcumin 
longa may stimulate beta cells in the pancreas to release more insulin (Wickenberg, 
Ingemansson, & Hlebowicz, 2010). 
Conclusion 
 This review brings to light some potential conflicting ingredients in Shred matrix. 
Caffeine can cause increases in central pressures and arterial stiffness, and also improve 
aerobic endurance (Mahmud & Feely, 2001; Pincomb et al., 1985; Sung et al., 1990). 
Garlic has been shown to decrease blood pressure through vasodilation, which may or 
may not offset caffeine’s vasoconstriction (Ried et al., 2013). Turmeric’s positive effects 
on arterial elasticity may also be negated by stiffening caused by caffeine in an acute 
dosage of Shred Matrix. 
 Simply because an ingredient is listed on the label of a product, it does not mean 
that the ingredient will cause any affect. Also, the proprietary blend posted on some 
supplement labels means that manufacturers do not have to disclose the amount of 
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ingredient contained within the product. Studies such as this will help determine various 
effects of supplements and provide speculation as to the causes observed. 
  
CHAPTER III 
METHODS 
 
The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke 
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse 
wave velocity, and body water distribution; 2) To investigate the differences between 
athletes and non-athletes on the previously stated measures. 
Subjects  
 Fifteen male and sixteen female participants between the ages of 18 and 40 years 
were recruited for this study. The length of testing for each subject was one 60 minute 
introduction session and two experimental sessions that lasted approximately 150 minutes 
each, for a total of 6 hours. 
Inclusion Criteria 
1. Subjects must have been between 18-40 years of age. 
2. Subjects must not have had hypertension, cardiovascular disease, any metabolic 
disease, chronic pain, or joint problems. 
3. Subjects must not have been taking any other ergogenic aid, with the exception of 
caffeine, for the previous 30 days. 
Exclusion Criteria 
1. Subjects that were taking medication for hypertension. 
2. Subjects that were taking medication for cardiovascular disease. 
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3. Subjects that were suffering from chronic pain. 
4. Subjects were suffering from joint injuries in the lower extremities. 
5. Subjects were currently or within the previous 30 days had consumed another 
ergogenic aid other than caffeine. 
Recruitment 
 Subjects were recruited from The University of Texas at Brownsville, Texas 
Southmost College and the surrounding community by fliers and word of mouth. 
Participation in this study was voluntary and subjects were allowed to withdraw at any 
time. 
Experimental Protocol 
 The first day included filling out paperwork and familiarization of testing 
protocols. Paperwork consisted of signing an informed consent form, completing the 
physical activity readiness questionnaire (PAR-Q), and a health status questionnaire. 
After completing paperwork, anthropometric measures that included height, weight, 
resting heart rate (HR), and resting blood pressure (BP) were assessed and recorded. 
Subjects then performed the Bruce Protocol. Testing consisted of running on a treadmill, 
with increasing speeds and incline, until exhaustion. Subjects were fitted with a mask for 
the metabolic cart, and gas exchange, perceived exertion, and heart rate were monitored 
continuously by the metabolic cart while performing VO2 Max testing. 
 For the two experimental protocols, participants were required to be fasted for at 
least 8 hours prior to testing. Sessions were randomized and either a placebo or Shred 
Matrix (MusclePharm Corp., Denver, CO, USA) were given on two separate days with at 
least 48 hours between each session. Upon arriving, subjects were required to give a urine 
sample measured by Clinical Urine Refractometer 300005 (SPER Scientific, Scottsdale, 
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AZ, USA) to determine hydration levels. If inadequately hydrated, subjects were 
instructed to drink water to reach proper hydration. Urine samples were continuously 
collected every 20 minutes until subjects were deemed hydrated according to preset 
standards. The subjects’ HR and BP were assessed prior to the start of exercise. 
Intracellular and extracellular body fluids were analyzed via Hydra ECF/ICF Model 4200 
Bio-Impedance Spectrum Analyzer (Xitron Technologies, Inc., San Diego, CA, USA). 
Baseline arterial compliance, left ventricular ejection time and fraction were recorded via 
the HDI/PulseWave CR-2000TM Research Cardio Vascular Profiling System 
(Hypertension Diagnostic, Inc., Eagan, Minnesota, USA). Baseline pulse wave velocity 
was also recorded prior to exercise via SphygmoCor® CPV Pulse Wave Analyzer (AtCor 
Medical, Itasca, IL, USA). During exercise, each subject exercised until volitional fatigue 
on a treadmill at 80% predicted VO2 Max. Immediately post exercise, arterial elasticity 
was measured at 0, 10, 20, and 40 minutes. Body fluid analyses were performed at 5 and 
30 minutes post-exercise. Pulse wave velocity was measured at 5, 15, 25, and 35 minutes 
post-exercise. During testing, heart rate, VO2, and RER was continuously monitored. 
Calibration of all the equipment was performed regularly according to instructions 
provided by the manufacturers.    
VO2MAX  
 Participants were required to wear a breathing mask that was connected to the 
MOXUS Modular VO2 System (AEI Technologies, Inc., Pittsburgh, PA, USA) through a 
mask and breathing tubes. Inspired oxygen and expired carbon dioxide was collected by 
the metabolic cart computer and analysis and calculations of energy expenditure and 
oxygen consumption was recorded by the software. Heart rate was assessed by wearing a 
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Polar Heart Rate Monitor FT7 Series (Polar Electro Inc., Lake Success, NY, USA) and 
recorded in the data collection sheet. 
Bruce Protocol 
 The Bruce Protocol consisted of multiple stages of increasing speeds and inclines 
until maximal exertion was reached. The metabolic cart recorded the exchange of gases 
inhaled and expired to indirectly determine how much oxygen was consumed. 
 
Table 1. Bruce Protocol 
Stage Minutes % grade  km/h MPH 
1 3 10 2.7 1.7 
2 6 12 4.0 2.5 
3 9 14 5.4 3.4 
4 12 16 6.7 4.2 
5 15 18 8.0 5.0 
6 18 20 8.8 5.5 
7 21 22 9.6 6.0 
Bioelectrical Impedance 
 Intracellular and extracellular fluid values were determined using the Xitron 4200 
Bio-Impedance Spectrum Analyzer. Subjects were placed in the supine position with 
arms held comfortably abducted from their bodies by roughly 15 degrees and legs 
separated comfortably. Electrodes were placed on the subjects’ left wrist and ankle. 
Hydration 
 Hydration status was measured using the SPER Scientific Clinical Urine 
refractometer. The device required 1-3 drops of a urine sample placed on a lens. The 
device was then pointed at a light source and the level of refraction caused by the sample 
was recorded. 
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Pulse Wave Analysis, Stroke Volume, and Ejection Time 
 Arterial compliance, stroke volume, and left ventricular ejection time were 
measured using the HDI/PulseWave CR-2000TM Research Cardio Vascular Profiling 
System. Subjects lay supine with their arms held comfortably abducted from their bodies 
by roughly 15 degrees and legs separated comfortably. The wrist was supported while 
measurements were being taken using the radial artery near the right hand wrist.  
 
Pulse Wave Velocity 
 Pulse wave velocity was measured by the SphygmoCor® Pulse Wave Analyzer. 
The subject had segmental measures taken with a segmometer (RealMet BCN, 
Barcelona, Spain) from the right carotid to right radial artery, the carotid to the right 
femoral artery, and also from the right femoral to the dorsalis pedis. Leads for ECG were 
placed at the top and bottom of the sternum and at the bottom of the rib cage near the 
midaxillary line. 
Statistical Analysis 
 A 3-way analysis of variance (ANOVA) (CONDITION [Placebo vs. Supplement] 
x TIME [varied depending on the variables] x CATEGORY [Male Athlete vs. Female 
Athlete vs. Male Non-Athlete vs. Female Non-Athlete]) with repeated measures and 
pairwise Bonferroni-adjusted estimated marginal means was used to see if significant 
differences existed for analyzed variables. All repeated measures data was checked with 
Mauchly’s Test of Sphericity. Where significant condition main effects were revealed, 
the origin of effects was determined by paired t-tests. An alpha of 0.05 was used to 
determine statistical significance and data was analyzed using SPSS 22.0 (IBM 
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Corporation, New York, NY, USA) and Microsoft Excel 2013 for Windows (Redmond, 
WA, USA). 
  
CHAPTER IV 
RESULTS 
 
The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke 
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse 
wave velocity, and body water distribution; 2) To investigate the differences between 
athletes and non-athletes on the previously stated measures. 
Subject Characteristics 
The study tested 31 subjects, including 15 athletes (age= 22.6 (3.1)) and 16 non-
athletes (age= 22.6 (3.9)) participants. Table 1 displays anthropometric measures of the 
study population. Subjects were recruited from the University of Texas at Brownsville 
campus, Texas Southmost College, and surrounding community. 
Table 2. Anthropometric Data of Participants 
Variables 
Athlete Male 
(n=7) 
Athlete Female 
(n=8) 
Non-Athlete 
Male (n=8) 
Non-Athlete 
Female (n=8) 
Combined 
Cohort (n=31) 
Age (yr) 23.57 (±3.7) 21.75 (±2.0) 23.13 (±4.1) 22 (±3.9) 22.6 (3.5) 
Height (cm) 174.29 (±4.7) 161.63 (±5.8) 179.25 (±6.7) 158.25 (±4.2) 168.16 (10.3) 
Weight (kg) 73.86 (±9.0) 56.63 (±7.0) 88.38 (±9.6) 61.13 (±12.2) 69.87 (15.7) 
VO2MAX 
(ml/kg/min) 
54.71 (±7.1) 52.45 (±8.6) 40.08 (±5.4) 36.15 (±3.8) 45.54 (10.1) 
Values are reported as means (SD). 
Body Water 
 Figures 1-2 show effects of exercise with and without supplement on athletes’ and 
non-athletes’ extracellular fluid. Except for condition main effect, categories (male 
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athlete vs. male non-athlete vs. female athlete vs. female non-athlete) were statistically 
similar (p>.05) for all effects and interactions and were reported together. Repeated 
measures ANOVA found significant condition (p=.012) and time (p<.001) main effects. 
Condition significance was determined by paired t-tests to originate in male non-athletes 
at Post5 (p=.023) and Post30 (p=.009). For time, Pre was significantly different from 
Post5 (p<.001) and Post30 (p<.001). Post5 was significantly different from Post30 
(p<.001). 
Figure 1. Athlete Extracellular Fluid. 
A= Males (N=7), B= Females (N=8) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 2. Non-Athlete Extracellular Fluid. 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males  at Post5 (p=.023) and Post30 (p=.009). *T significant 
time difference (p<.001). Values reported as mean ±SE. 
 
Figure 3 shows effects of exercise with and without supplement on athletes’ 
intracellular fluid. Repeated measures ANOVA detected a significant time (p<.001) 
effect. For time, Pre was significantly different from Post30 (p<.001). Post5 was 
significantly different from Post30 (p<.001). 
Figure 3. Athlete Intracellular Fluid. 
 
A= Males (N=7), B= Females (N=8) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 4 shows effects of exercise with and without supplement on non-athlete 
intracellular fluid. Repeated measures ANOVA showed significance for the time 
(p<.001) main effect. For time, Pre was significantly different from Post30 (p<.001). 
Post5 was significantly different from Post30 (p<.001). 
Figure 4. Non-Athlete Intracellular Fluid. 
 
A= Males (N=7), B= Females (N=8) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
 
Figures 5-6 shows effects of exercise with and without supplement on athlete and 
non-athlete urine specific gravity. Categories were statistically similar (p>.05) for all 
effects and interactions; therefore, they were reported together. Repeated measures 
ANOVA showed significant time (p<.001) differences. For time, Pre was significantly 
different from Post5 (p=.009) and Post30 (p<.001). Post5 was significantly different 
from Post30 (p<.001). 
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Figure 5. Athlete Urine Specific Gravity. 
 
A= Males (N=7), B= Females (N=7) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 6. Non-Athlete Urine Specific Gravity. 
 
A= Males (N=8), B= Females (N=8) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
 
Hemodynamic Responses 
 Figures 7-8 show effects of exercise with and without supplement on athlete and 
non-athlete systolic blood pressure. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
Repeated measures ANOVA showed significant condition (p=.001) and time (p=<.001) 
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main effects, and a trend for condition*time interaction (p=.067). For condition, paired t-
tests showed significance originated for male athletes at Post10 (p=.047) and Post20 
(p=.01). For time, pre was significantly different from Post0 (p<.001) and Post40 
(p=.038). Post0 was significantly different from Post10 (p<.001) and Post20 (p<.001). 
Figure 7. Athlete Systolic Blood Pressure 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post10 (p=.047) and Post 20 (p=.01). *T significant 
time difference (p<.001). Values reported as mean ±SE. 
 
Figure 8. Non-Athlete Systolic Blood Pressure 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
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Figures 9-10 show effects of exercise with and without supplement on athlete and 
non-athlete diastolic blood pressure. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
Repeated measures ANOVA showed main effects for condition (p=.003) and time 
(p=<.001), and a significant interaction for time*category (p=.042). For condition, paired 
t-tests showed significance originated for male athletes at Post20 (p=.035) and for female 
athletes at Post40 (p=.021). For time, Pre was significantly different from Post0 
(p=.003). Post0 was significantly different from Post10 (p<.001), Post20 (p<.001), and 
Post40 (p<.001). 
Figure 9. Athlete Diastolic Blood Pressure 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post20 (p=.035) and females at Post40 (p=.021). *T 
significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 10. Non-Athlete Diastolic Blood Pressure 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figures 11-12 show effects of exercise with and without supplement on athlete 
and non-athlete mean arterial pressure. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
Repeated measures ANOVA showed significant main effects for condition (p=.001) and 
time (p=<.001), and a trend for condition*category (p=.061) interaction. For condition, 
paired t-tests showed significance originated in male athletes at Post20 (p=.046), female 
athletes at Post10 (p=.037) Post20 (p=.048) and Post40 (p=.029), and in male non-
athlete at Post10 (p=.014) and Post20 (p=.044). For time, Pre was significantly different 
from Post0 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20 
(p<.001), and Post40 (p<.001). Post 10 was significantly different from Post20 (p=.043) 
and Post40 (p=.024). 
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Figure 11. Athlete Mean Arterial Pressure 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post20 (p=.046) and females at Post10 (p=.037) Post20 
(p=.048) and Post40 (p=.029). *T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 12. Non-Athlete Mean Arterial Pressure 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post10 (p=.014) and Post20 (p=.044). *T significant 
time difference (p<.001). Values reported as mean ±SE. 
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Figures 13-14 shows effects of exercise with and without supplement on athlete 
and non-athlete pulse pressure. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
Repeated measures ANOVA showed significant condition (p=.035) and time (p=<.001) 
main effects. For condition, paired t-tests showed significance originated in male non-
athletes at Post40 (p=.011). For time, Pre was significantly different from Post0 
(p<.001). Post0 was significantly different from Post10 (p<.001), Post20 (p<.001), and 
Post40 (p<.001). 
Figure 13. Athlete Pulse Pressure 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 14. Non-Athlete Pulse Pressure 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post40 (p=.011) *T significant time difference 
(p<.001). Values reported as mean ±SE. 
 
Figure 15 shows effects of exercise with and without supplement on athlete pulse 
rate. Repeated measures ANOVA showed significant interactions for condition*time 
(p=.001), condition*category (p=.009), time*category (p=.001), and significant 
condition (p=.001) and time (p<.001) main effects. Both athlete groups had lower 
exercise heart rates for each time point compared to their non-athlete counterparts. For 
condition, paired t-tests showed significance originated in female athletes at Post10 
(p=.038). For time, Pre was significantly different from Post0 (p<.001), Post10 (p<.001), 
Post20 (p<.001), and Post40 (p<.001). Post0 was significantly different from Post10 
(p<.001), Post20 (p<.001), and Post40 (p<.001). Post10 was significantly different from 
Post20 (p<.001) and Post40 (p<.001). Post 20 was significantly different from Post40 
(p<.001). 
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Figure 15. Athlete Pulse Rate 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for females at Post10 (p=.038). *T significant time difference 
(p<.001). Values reported as mean ±SE. 
 
Figure 16 shows effects of exercise with and without supplement on non-athlete 
pulse rate. Repeated measures ANOVA showed significant interactions for 
condition*time (p=.001), condition*category (p=.009), time*category (p=.001), and 
significant main effects for condition (p=.001) and time (p<.001). For condition, paired 
t-tests showed significance originated in male non-athletes at Post0 (p=.014), Post10 
(p<.001), Post20 (p=.004), and Post40 (p=.009). For time, Pre was significantly different 
from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001). Post0 was 
significantly different from Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001). 
Post10 was significantly different from Post20 (p<.001) and Post40 (p<.001). Post 20 
was significantly different from Post40 (p<.001). 
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Figure 16. Non-Athlete Pulse Rate 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post0 (p=.014), Post10 (p<.001), Post20 (p=.004), and 
Post40 (p=.009). *T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figures 17-18 show effects of exercise with and without supplement on athlete 
and non-athlete cardiac ejection time. Categories were statistically similar (p>.05) for all 
effects and interactions and were reported together. Repeated measures ANOVA showed 
a significant time (p<.001) main effect. For time, Pre was significantly different from 
Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001). Post0 was 
significantly different from Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001).  
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Figure 17. Athlete Cardiac Ejection Time 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 18. Non-Athlete Cardiac Ejection Time 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figures 19-20 show effects of exercise with and without supplement on athlete 
and non-athlete stroke volume. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and are reported together. 
Repeated measures ANOVA showed a significant condition*time interaction (p=.016), 
condition main effect (p=.033), and time main effect (p<.001). For condition, paired t-
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tests showed significance originated in non-athlete females at Post0 (p=.012). For time, 
Pre was significantly different from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), 
and Post40 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20 
(p<.001), and Post40 (p<.001). Post10 was significantly different from Post20 (p<.001) 
and Post40 (p<.001). Post 20 was significantly different from Post40 (p<.001). 
Figure 19. Athlete Stroke Volume 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 20. Non-Athlete Stroke Volume 
 
A= Males (N=7), B= Females (N=8) 
*@ Condition difference for females at Post0 (p=.012). *T significant time difference (p<.001). Values 
reported as mean ±SE. 
 
Figures 21-22 show effects of exercise with and without supplement on athlete 
and non-athlete stroke volume index. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and are reported together. 
Repeated measures ANOVA showed a significant condition*time (p=.001) interaction, 
and condition (p=.007) and time (p<.001) main effects. For condition, paired t-tests 
showed significance originated in non-athlete females at Post0 (p=.013). For time, Pre 
was significantly different from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and 
Post40 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20 
(p<.001), and Post40 (p<.001). Post10 was significantly different from Post20 (p<.001) 
and Post40 (p<.001). Post 20 was significantly different from Post40 (p=001). 
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Figure 21. Athlete Stroke Volume Index 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 22. Non-Athlete Stroke Volume Index 
 
A= Males (N=7), B= Females (N=8) 
*@ Condition difference for females at Post0 (p=.013). *T significant time difference (p<.001). Values 
reported as mean ±SE. 
 
Figures 23-24 shows effects of exercise with and without supplement on athlete 
and non-athlete cardiac output. Categories were statistically similar (p>.05) for all effects 
and interactions and are reported together. Repeated measures ANOVA showed a 
significant main effect for time (p<.001) and a trend for condition*time (p=.081) 
interaction. For time, Pre was significantly different from Post10 (p<.001), Post20 
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(p<.001), and Post40 (p=.001). Post0 was significantly different from Post10 (p<.001) 
and Post20 (p=.003). Post 20 was significantly different from Post40 (p=.006). 
Figure 23. Athlete Cardiac Output 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 24. Non-Athlete Cardiac Output 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figures 25-26 show effects of exercise with and without supplement on athlete 
and non-athlete vascular resistance. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
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Repeated measures ANOVA showed significant condition (p=.05) and time (p<.001) 
main effects. For condition, paired t-tests showed significance originated in male athletes 
at Post 20 (p=.017) and female athletes at Post20 (p=.018) and Post40 (p=.032).  For 
time, Pre was significantly different from Post10 (p<.001), Post20 (p<.001), and Post40 
(p<.001). Post0 was significantly different from Post10 (p=.008) and Post20 (p=.035). 
Figure 25. Athlete Vascular Resistance 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post 20 (p=.017) and females at Post20 (p=.018) and 
Post40 (p=.032). *T significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 26. Non-Athlete Vascular Resistance 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
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Figures 27-28 show effects of exercise with and without supplement on athlete 
and non-athlete vascular impedance. Categories were statistically similar (p>.05) for all 
effects and interactions and were reported together. Repeated measures ANOVA showed 
a significant time (p<.001) main effect and a trend for condition (p=.076) main effect. 
For time, Pre was significantly different from Post10 (p<.001), Post20 (p<.001), and 
Post40 (p=.014). Post0 was significantly different from Post10 (p<.001) and Post20 
(p=.003). Post10 was significantly different from Post40 (p=.042). 
Figure 27. Athlete Vascular Impedance 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
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Figure 28. Non-Athlete Vascular Impedance 
 
A= Males (N=7), B= Females (N=8) 
*T significant time difference (p<.001). Values reported as mean ±SE. 
 
Arterial Compliance 
 Figures 29-30 show effects of exercise with and without supplement on 
athlete and non-athlete pulse wave velocity from the carotid to radial artery. Except for 
condition main effect, categories were statistically similar (p>.05) for all effects and 
interactions and were reported together. Repeated measures ANOVA showed significant 
condition (p=.01) and time (p=<.001) main effects. For condition, paired t-test analysis 
showed significance originated in female athletes at Post15 (p=.032) and Post25 
(p=.019). For time, Pre was significantly different from Post10 (p=.004), Post20 
(p=.008), and Post40 (p=.017). 
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Figure 29. Athlete Pulse Wave Velocity- Carotid to Radial 
 
A= Males (N=7), B= Females (N=7) 
*@ Significant condition difference for females at Post15 (p=.032) and Post25 (p=.019). *T Significant 
time difference (p<.001). Values reported as mean ±SE. 
 
Figure 30. Non-Athlete Pulse Wave Velocity- Carotid to Radial 
 
A= Males (N=8), B= Females (N=7) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 31 shows effects of exercise with and without supplement on athlete pulse 
wave velocity from the carotid to femoral segment. Repeated measures ANOVA showed 
a significant condition*time (p=.01) and condition*category (p=.038) interaction. There 
was also a significant condition (p=.003) main effect. Paired t-test analysis showed 
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condition significance originated in male athletes at Post15 (p=.027) and Post35 (p=.005) 
and in female athletes at Post35 (p=.016). 
Figure 31. Athlete Pulse Wave Velocity- Carotid to Femoral 
 
A= Males (N=7), B= Females (N=6) 
*@ Significant condition difference for males at Pos t 15 (p=.027) and Post35 (p=.005) and for females 
at Post35 (p=.016). Values reported as mean ±SE. 
 
Figure 32 shows effects of exercise with and without supplement on non-athlete 
pulse wave velocity from the carotid to femoral segment. Repeated measures ANOVA 
showed a significant condition*time (p=.01) and condition*category (p=.038) 
interaction. There was also a significant main effect for condition (p=.003). Paired t-test 
analysis showed condition significance originated in female non-athletes at Post15 
(p=.016) and Post25 (p=.03). There was no significant condition effect found for male 
non-athletes. 
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Figure 32. Non-Athlete Pulse Wave Velocity- Carotid-Femoral 
 
A= Males (N=8), B= Females (N=7) 
*@ Significant condition difference for females at Post15 (p=.016) and Post25 (p=.03). Values reported 
as mean ±SE. 
 
Figures 33-34 show effects of exercise with and without supplement on athlete 
and non-athlete pulse wave velocity from the femoral to distal segment. Categories were 
statistically similar (p>.05) for all effects and interactions and were reported together. 
Repeated measures ANOVA showed a significant condition*time (p=.018) interaction. 
There was also a significant time (p=<.001) main effect. For time, Pre was significantly 
different from Post0 (p<.001), Post10 (p=.001), and Post20 (p=.006). Post0 was 
significantly different from Post20 (p=.009), and Post40 (p=.046). 
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Figure 33. Athlete Pulse Wave Velocity- Femoral to Distal 
 
A= Males (N=7), B= Females (N=7) 
*T Significant time difference (p<.001).Values reported as mean ±SE. 
 
Figure 34. Non-Athlete Pulse Wave Velocity- Femoral to Distal 
 
A= Males (N=8), B= Females (N=7) 
*@ Significant condition difference for males at Post25 (p=.021) and Post35 (p=.01). *T Significant 
time difference (p<.001). Values reported as mean ±SE. 
 
Figures 35-36 show effects of exercise with and without supplement on athlete 
and non-athlete large arterial elasticity. Except for condition main effect, categories were 
statistically similar (p>.05) for all effects and interactions and are reported together. 
Repeated measures ANOVA showed significant condition (p=.003) and time (p=<.001) 
main effects. There was also a trend for condition*time (p=.096) interaction. For 
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condition, paired t-test analysis showed significance originated in male athletes at Post20 
(p=.05) and in female athletes at Post10 (p=.012). For time, Pre was significantly 
different from Post0 (p=.001). Post0 was significantly different from Post10 (p<.001), 
Post20 (p<.001), and Post40 (p=.001). 
Figure 35. Athlete Large Arterial Elasticity 
 
A= Males (N=7), B= Females (N=8) 
*@ Significant condition difference for males at Post20 (p=.05) and females at Post10 (p=.012).  
*T Significant time difference (p<.001). Values reported as mean ±SE. 
 
Figure 36. Non-Athlete Large Arterial Elasticity 
 
A= Males (N=6), B= Females (N=7) 
*T Significant time difference (p<.001). Values reported as mean ±SE. 
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Substrate Utilization 
 Figures 37-38 show effects of exercise with and without supplement on athlete 
and non-athlete respiratory exchange ratio. Except for condition main effect, categories 
were statistically similar (p>.05) for all effects and interactions and are reported together. 
Repeated measures ANOVA showed significant condition (p=.034) time (p=.001) main 
effects through 15 minutes of treadmill running. VO2 and heart for the same time length 
was not statistically significant for condition. For condition, paired t-test analysis showed 
significance originated in male non-athletes at min3 (p=.003), min6 (p=.03), min9 
(p=.025), and min12 (p=.025). For time, Post0 was significantly different from Post10 
(p<.001), Post20 (p=.001), and Post40 (p=.001). 
Figure 37. Athlete Respiratory Exchange Ratio 
 
A= Males (N=7), B= Females (N=7) 
*T significant time difference (p=.001). Values reported as mean ±SE. 
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Figure 38. Non-Athlete Respiratory Exchange Ratio 
 
A= Males (N=5), B= Females (N=6)  
*@ Significant condition difference for males at min3 (p=.003), min6 (p=.03), min9 (p=.025), and min12 
(p=.025). *T significant time difference (p=.001). Values reported as mean ±SE. 
 
Endurance 
  Figure 39 shows athlete running times with and without supplement to volitional 
fatigue. Male athletes ran 36.47 (±15.83) minutes on the placebo and 41.28 (±20.99) 
minutes on the supplement.  Female athletes ran 21.71 (±2.95) minutes on the placebo 
and 22.1 minutes (±2.49) on the supplement.  
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Figure 39. Athlete Running Time 
 
A= Males (N=7), B= Females (N=8) 
Values reported as mean ±SE. 
 
Figure 40 shows non-athlete running times of exercise with and without 
supplement to volitional fatigue. There was a significant difference for running time to 
volitional fatigue for female non-athletes (p=.033). Male non-athletes ran 29.27 (±4.76) 
on the placebo and 28 (±4.01) minutes on the supplement. Female non-athletes ran 23.64 
(±2.94) minutes on the placebo and 25.31 (±2.67) minutes on the supplement. 
Figure 40. Non-Athlete Running Time 
 
A= Males (N=7), B= Females (N=8) 
# Significant time to volitional fatigue for females (p=.033). Values reported as mean ±SE. 
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CHAPTER V 
DISCUSSION 
 
The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke 
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse 
wave velocity, and body water distribution; 2) To investigate the differences between 
athletes and non-athletes on the previously stated measures. 
Body Water 
 There were no significant differences between conditions for the combined cohort 
of for any individual group for urine specific gravity. Based on these results, it can be 
assumed that hydration did not play a role for hemodynamic responses or performance 
for running time to exhaustion. 
Extracellular fluid differences for the supplement condition in male non-athletes 
were also not a barrier to performance. While post exercise ECF levels were lower in the 
supplement condition, they did not drop below pre-exercise values. Intracellular fluids for 
the same group and condition also did not drop below the pre-exercise levels, indicating 
that there was no drop in total body water from sweating that would cause a decrease in 
performance in relation to the placebo condition (Case et al., 2000). 
Though the supplement contains the diuretics dandelion root and uva ursi leaf, an 
acute dosage did not appear to have any measurable effect on hydration or total body 
water, though the male non-athletes showed lower ECF during the supplement condition. 
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Had the supplement caused an acute effect through diuresis, there should have been a 
lowering of blood pressure from lower systemic blood volume, however none was found. 
Caffeine has also been found in some instances to be a mild diuretic. However, 
the literature suggests that the diuresis is similar to that caused by drinking plain water. 
The reported effects indicate there is no evidence for enough water loss from caffeine to 
cause any decreases in performance (Armstrong, 2002).  
Hemodynamic Responses 
 There were significant differences in blood pressures between conditions post-
exercise. The condition*time interaction showed that the increase in systolic blood 
pressure was directly related to the taking of the supplement. This finding is similar to 
another study that observed the effects of caffeine supplementation on exercise, 
consisting of submaximal, followed by maximal cycling. The authors speculated that the 
increase in systolic and diastolic pressure was caused by increases in vascular resistance 
from peripheral vasoconstriction. The vasoconstriction was caused by caffeine’s 
antagonist effects on the vasodilator, adenosine, and epinephrine’s activation of alpha-1 
receptors in the smooth muscle of the arteries (Pincomb et al., 1985; Sung et al., 1990). 
Evidence that caffeine is the cause for increases in central pressures in this study is 
furthered supported by significant increases in vascular resistance, diastolic blood 
pressure, mean arterial pressure, pulse pressure, pulse rate and decreased stroke volume. 
Another study evaluating the effects of a thermogenic supplement during and 
after exercise found increases in heart rate, systolic blood pressure, and diastolic blood 
pressure. Subjects (13 women, 15 men) ingested a supplement containing caffeine, 
capsaicin, and other ingredients, rested for approximately 50 minutes, and then walked on 
a treadmill at a self-selected pace for an hour. Though the study did not have subjects 
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exercise at vigorous intensity, heart was significantly elevated above resting values, 
allowing similar effects to occur post-exercise compared to the current study (Ryan et al., 
2009). 
 Condition*time interactions were observed for pulse rate and stroke volume, but 
there was no significant difference in total cardiac output between conditions. Higher 
pulse rates for the supplement condition led to a decreased stroke volume from shorter 
duration left ventricular filling. The placebo condition showed slower heart rates with 
larger stroke volumes.  
 It appears that garlic had no effect on blood pressure in this study. This was either 
due to an ineffectively low dosage, interference from caffeine, subject sampling from a 
non-hypertensive population, or varied combinations of the three. For athletes, results of 
the current study coincide with the study performed by Morris et al. (2013) that found no 
significant differences in blood pressures in athletes cycling under hypoxic conditions. 
The other study mentioned previously, by Ried et al. (2013), concerning garlic, showed 
significant decreases in blood pressure. However, the subjects in the study were 
considered hypertensive. In the current study, all subjects were normotensive or 
prehypertensive. 
Arterial Compliance 
 Both pulse wave velocity and arterial elasticity measures showed an increase in 
stiffness of the large arteries above the placebo condition. This evidence is supported by 
the previously mentioned article by Mahmud and Feely (Mahmud & Feely, 2001). While 
their study did not observe subjects during or post-exercise, negative changes in pulse 
wave velocity at rest caused by caffeine are a plausible indication that the same effects 
can be observed from exercise. 
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 Another study performed on young and healthy males and females also showed 
increases in arterial stiffness with increases in pulse wave velocity after ingestion of 
caffeine. In their study, 8 males and eight females ingested 80mg of caffeinated or 
decaffeinated coffee on separate visits. Subjects were then monitored at rest and 
measurements were taken every thirty minutes for two hours. Diastolic blood pressure 
was also found to be higher in the caffeine condition (Karatzis et al., 2005). 
 An acute dosage of turmeric from the supplement did not have an effect on post-
exercise arterial stiffness outcomes. There was either not enough turmeric in the dosage 
to see a response, caffeine masked any benefits derived, or it may take a longitudinal 
study to observe the same positive effects seen from the study by Akazawa et al (2013). 
Substrate Utilization 
 The supplement caused a significantly higher respiratory exchange ratio through 
the first 15 minutes of exercise, especially in male non-athletes. Due to loss of statistical 
power for groups after 15 minutes, no further time points were included. The higher RER 
indicates that a higher rate of glycolysis was being used to meet energy demands (Powers 
& Howley, 2009, pp. 59-60).  
 Eleutherococcus senticosus (ES) has been previously shown to increase 
endurance in recreationally trained men participating in an 8 week training study (Kuo, 
2010). The current study containing ES contradicts those findings. However, the 
previously mentioned study was a training study, not acute, they performed cycling 
exercise at 75% VO2, and the supplement did not include other ingredients that may 
interfere. 
 Other ingredients that affect blood glucose, including capsaicin, gymnema 
sylvestre, and banaba extract were mentioned in the literature review. These ingredients 
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have been previously found to affect how carbohydrate is absorbed and the effects on 
insulin response (Al-Romaiyan et al., 2010; Dömötör et al., 2006; Fernandez-Mejia, 
2005; Kang et al., 2010; Kurian et al., 2014; Tsuchibe et al., 2006; Weerapan 
Khovidhunkit, 2009). Because this study required that subjects be fasted for participation, 
there was no measurable effect these ingredients had on their intended purposes. 
Endurance 
 Overall, there were no significant differences between the supplement and 
placebo conditions. Female non-athletes alone showed significantly longer time to 
volitional fatigue. Graham and Spriet (1995) have previously shown that various dosages 
of caffeine affect well-trained endurance athletes differently depending on the dosage. In 
their study, subjects ingested a placebo, 3 mg/kg, 6 mg/kg, or 9 mg/kg of caffeine. After a 
period of rest, subjects ran at 85% of their VO2MAX until volitional fatigue. The times to 
exhaustion varied between groups, but only the 3 and 6 mg/kg trial lasted significantly 
longer. A notable finding from the study is that only the 9 mg/kg trial had significant 
increases in plasma FFA and glycerol with the greatest effect on epinephrine. This should 
have correlated to higher FFA use and glycogen sparing, but time to exhaustion indicated 
that it was not the most effective condition (Graham & Spriet, 1995). 
 In the current study, the dosage of supplement was uniform for all subjects, 
meaning caffeine ingestion was relatively different for individuals and between groups. 
The supplement in the current study contained 217.5 mg of caffeine per serving 
according to its label. This equated to male athletes receiving an average of 2.94 mg/kg, 
female athletes 3.84 mg/kg, male non-athletes 2.46 mg/kg, and female non-athletes 
ingested 3.56 mg/kg of caffeine. Dosages appear to be similar for all groups in the current 
study. However, it has also been shown that tolerance to habitual caffeine use can affect 
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treadmill running time to exhaustion at a similar intensity of 75% V02 max (Fisher, 
McMurray, Berry, Mar, & Forsythe, 1986). The members of the female non-athlete group 
might consume less caffeine daily compared to the other groups, showing less tolerance, 
and resulting in an increased time to exhaustion. This is a possible explanation as to why 
the group was the only one to last significantly longer.  
 
CONCLUSION 
 
 The purpose of this study was to 1) examine the acute effects of the weight loss 
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke 
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse 
wave velocity, and body water distribution; 2) To investigate the differences between 
athletes and non-athletes on the previously stated measures. This study asked: Was there 
a significant increase in fat metabolism when the weight loss aid, Shred Matrix, is 
consumed prior to exercise? What were the changes in exercise HR, exercise diastolic 
and systolic BP? Was there a significant effect on stroke volume? Was there a significant 
effect on ejection time? Was there an increase in exercise endurance? Was there a change 
in arterial compliance? Was there a significant effect on pulse wave velocity? Was there a 
change in intracellular and/or extracellular body water? 
 
Research Hypothesis 1. There was a greater amount of fat metabolism with Shred 
matrix during exercise. 
 The results of the present study did not support this hypothesis. It was 
hypothesized that caffeine would mobilize more fatty acids from adipose tissue and spare 
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glycogen stores. However, RER values, especially in male non-athletes, indicated an 
increased use of carbohydrate during the first 15 minutes of treadmill running at 80% of 
VO2MAX.  
 
Research Hypothesis 2. Shred Matrix resulted in lower increases in HR, diastolic 
and systolic blood pressures at different time points compared to placebo. 
 The results of the present study did not support this hypothesis. Based on a study 
by McClaran and Wetter (2007), we hypothesized that caffeine would cause a lower heart 
rate response during sub-maximal exercise. However, Shred Matrix resulted in no 
significant difference during exercise for heart rate.  
 Due to garlic’s vasodilation capabilities reported in a previously mentioned study, 
we hypothesized that peripheral vascular resistance would be lower with the supplement. 
Lower resistance would bring about lower blood pressures. Pulse rate, SBP, and DBP 
were all higher post-exercise for Shred Matrix compared to the placebo at different time 
points. 
 
Research Hypothesis 3. There was a significant increase in stroke volume. 
 The results of the present study did not support this hypothesis. It was 
hypothesized that the expected lower heart rate would leave more time for left ventricular 
filling and result in increased stroke during systole with the supplement condition. 
However, stroke volume was lower post-exercise compared to the placebo. 
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Research Hypothesis 4. There was an increase in cardiac ejection time. 
 The evidence gathered in the present study did not support the hypothesis. With 
the expected lower heart and longer stroke volume, it was expected that cardiac ejection 
time would last longer with the supplement. However, the present study did not find any 
significant changes in CET. 
 
Research Hypothesis 5. Shred Matrix resulted in increased time to exhaustion. 
 The results of the present study did not support this hypothesis. The hypothesized 
increase in fat metabolism and subsequent glycogen sparing would potentially allow 
subjects to continue running for a longer duration. Overall mean time to exhaustion was 
higher for Shred Matrix, but was only significant for female non-athletes. 
 
Research Hypothesis 6. There was an increase in large and small arterial elasticity. 
 The results of the present study did not support this hypothesis. With the 
hypothesized decrease in vascular resistance, there would be a decrease in central and 
peripheral pressures, allowing increased arterial compliance. However, shred matrix 
caused decreases in large arterial elasticity and no changes for small arterial elasticity 
compared to the placebo. 
 
Research Hypothesis 7. There was a decrease in pulse wave velocity. 
 The results of the present study did not support this hypothesis. Hypothesized 
decreases in vascular resistance and increased arterial elasticity would also cause lower 
wave reflections, placing less strain on the heart, and result in decreased pulse wave 
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velocity (Nichols et al., 2008). Shred matrix caused in increase in pulse wave velocity 
compared to the placebo. 
 
Research Hypothesis 8. There was an increase in extracellular water. 
 The results of the present study did not support this hypothesis. It was 
hypothesized that with the presence of potassium aspartate, there was a possibility of a 
fluid shift from extracellular to intracellular fluid. Non-athlete males were the only group 
to undergo significant changes in extracellular fluid. The ECF for male non-athletes was 
lower than the placebo. 
 This study observed acute negative effects for multiple variables. These included 
higher blood pressures, lower arterial elasticity, and increased pulse wave velocity post-
exercise during days where Shred Matrix was ingested compared to a placebo. These 
measures indicate an increased risk for a possible cardiovascular event (Mahmud & 
Feely, 2001; Papaioannou, Karatzi, Karatzis, Papamichael, & Lekakis, 2005).  
 Simply because a weight loss supplement is marketed for athletes does not mean 
it is recommended to take. The term “athlete” encompasses a vast array of sports 
requiring different energy demands. In the present study where higher intensities of 
aerobic running were used, athletes did not statistically perform better while on the 
supplement. Furthermore, if chronic use does cause a measurable diuretic effect, the loss 
of water could have a negative effect on athletic performance and can even become a 
safety concern (Case et al., 2000). 
Both athletes and non-athletes should educate themselves before purchasing 
supplements to determine both effectiveness and potential harmful effects. Also, 
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conversing with a physician may help determine if a supplement is safe or if a preexisting 
condition exists that makes taking a supplement contraindicated. 
To ameliorate caffeine’s negative effects on hemodynamics and arterial 
compliance, supplement manufacturers should look into reformulating products in an 
effort to offset those negative effects. For example, the current supplement could be 
modified to use more garlic and turmeric in relation to caffeine to improve vasodilation 
and arterial elasticity.  
 It is recommended that future studies involving weight loss supplements 
containing ingredients affecting carbohydrate absorption incorporate carbohydrate 
feeding so that insulin effects can be measured in addition to performance. Long-term 
studies can also be conducted testing products containing diuretics and their effects on 
both athletic performance and cardiovascular health. 
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FDA -Food and Drug Administration 
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ICF -Intracellular Fluid 
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PAR-Q -Physical Activity Readiness Questionnaire 
PP -Pulse Pressure 
PPAR -Peroxisome Proliferator-Activated Receptor 
PR -Pulse Rate 
PWV -Pulse Wave Velocity 
RER -Respiratory Exchange Ration 
SAE -Small Arterial Elasticity 
SBP -Systolic Blood Pressure 
SV -Stroke Volume 
SVI -Stroke Volume Index 
USG -Urine Specific Gravity 
VI -Vascular Impedance 
VR -Vascular Resistance 
 
72 
 
Appendix B. Recruitment Flyer 
 
  
73 
 
Appendix C. Informed Consent  
 
74 
 
75 
 
76 
 
 
  
77 
 
Appendix D. PAR-Q 
 
  
78 
 
Appendix E. IRB Approval Letter 
  
79 
 
Appendix F. Data Collection Sheet 
 
